Chemed Corporation (NYSE:CHE) Stock Now Rated “Hold” by Sell-Side Brokerages

Shares of Chemed Corporation (NYSE:CHE) have been given an average rating of “Hold” by the seven analysts that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $530.75.

CHE has been the topic of a number of recent analyst reports. UBS Group began coverage on shares of Chemed in a research note on Friday. They set a “buy” rating on the stock. Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Oppenheimer boosted their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada increased their price objective on shares of Chemed from $436.00 to $548.00 and gave the company a “sector perform” rating in a report on Thursday, July 30th.

Chemed Stock Performance

Shares of CHE stock opened at $495.57 on Friday. Chemed has a 12-month low of $365.20 and a 12-month high of $557.00. The firm has a market capitalization of $6.48 billion, a price-to-earnings ratio of 24.89, a price-to-earnings-growth ratio of 2.00 and a beta of 0.51. The business has a 50 day simple moving average of $523.26 and a 200 day simple moving average of $458.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89.

Chemed (NYSE:CHE) last announced its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating the consensus estimate of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%.The firm had revenue of $673.25 million for the quarter, compared to the consensus estimate of $665.04 million. During the same quarter in the previous year, the business earned $4.27 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, equities research analysts anticipate that Chemed will post 23.55 EPS for the current year.

Chemed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 0.6%. This is a positive change from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. Chemed’s payout ratio is currently 14.06%.

Insider Buying and Selling at Chemed

In other news, Director Patrick Grace sold 190 shares of Chemed stock in a transaction on Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the transaction, the director directly owned 3,533 shares in the company, valued at approximately $1,879,556. This trade represents a 5.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Spencer Lee sold 1,000 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $541.04, for a total value of $541,040.00. Following the completion of the sale, the executive vice president directly owned 13,912 shares in the company, valued at $7,526,948.48. This represents a 6.71% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 7,190 shares of company stock valued at $3,806,260. 3.33% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in shares of Chemed during the 2nd quarter worth $1,726,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Chemed during the second quarter worth $4,413,000. TD Asset Management Inc lifted its holdings in shares of Chemed by 7.5% during the fourth quarter. TD Asset Management Inc now owns 324,546 shares of the company’s stock valued at $138,860,000 after purchasing an additional 22,715 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of Chemed in the 2nd quarter valued at $9,281,000. Finally, Lone Peak Global Investors LLC increased its stake in Chemed by 38.1% in the 2nd quarter. Lone Peak Global Investors LLC now owns 37,099 shares of the company’s stock worth $17,279,000 after purchasing an additional 10,226 shares in the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

About Chemed

Chemed Corporation is a diversified holding company that operates businesses in the healthcare and residential and commercial services industries. Its primary operations are conducted through VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services are delivered in patients’ homes, hospice residences, nursing facilities, hospitals and other care settings, primarily throughout the United States. Care is provided by interdisciplinary teams that may include physicians, nurses, hospice aides, social workers and chaplains.

Roto-Rooter provides plumbing and drain-cleaning services, as well as water cleanup and related services for residential and commercial customers.